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Trichloroethylene (TCE) pharmacokinetics have been studied in experimental animals and humans
for over 30 years. Compartmental and physiologically based pharmacokinetic (PBPK) models have
been developed for the uptake, distribution, and metabolism ofTCE and the production, distribution,
metabolism, and elimination of P450-mediated metabolites of TCE. TCE is readily taken up into
systemic circulation by oral and inhalation routes of exposure and is rapidly metabolized by the
hepatic P450 system and to a much lesser degree, by direct conjugation with glutathione. Recent
PBPK models for TCE and its metabolites have focused on the major metabolic pathway for
metabolism of TCE (P450-mediated metabolic pathway). This article briefly reviews selected
published compartmental and PBPK models for TCE. Trichloroacetic acid (TCA) is considered a
principle metabolite responsible for TCE-induced liver cancer in mice. Liver cancer in mice was
considered a critical effect by the U.S. Environmental Protection Agency for deriving the current
maximum contaminant level for TCE in water. In the literature both whole blood and plasma
measurements of TCA are reported in mice and humans. To reduce confusion about disparately
measured and model-predicted levels of TCA in plasma and whole blood, model-predicted
outcomes are compared for first-generation (plasma) and second-generation (whole blood) PBPK
models published by Fisher and colleagues. Qualitatively, animals and humans metabolize TCE in a
similar fashion, producing the same metabolites. Quantitatively, PBPK models for TCE and its
metabolites are important tools for providing dosimetry comparisons between experimental animals
and humans. TCE PBPK models can be used today to aid in crafting scientifically sound public
health decisions forTCE. Key words: chloral hydrate, dichloroacetic acid, human, metabolism, PBPK
models, pharmacokinetics, rodents, trichloroacetic acid, trichloroethanol, trichloroethylene.
- Environ Health Perspect 108(suppl 2):265-273 (2000).
http.//ehpnetl.niehs.nih.gov/docs/2000/suppl-2/265-273fisher/abstract.html
Pharmacokinetic Modeling
and Trichloroethylene
Trichloroethylene (TCE) is now a widespread
environmental contaminant in the United
States because ofits historical use as adegreaser
in the 1960s and 1970s. Occupational health
concerns for TCE vapors began in the 1970s
in Europe and the United States, which
prompted the publication oftwo human phar-
macokinetic models for TCE. The utility of
human pharmacokinetic models was recog-
nized at this time as a tool to quantify individ-
ual exposure to TCE vapor. Sato et al. (1)
published a 3-compartment human model to
describe the systemic clearance ofTCE from
blood and the urinary excretion ofmetabolites
(trichloroacetic acid [TCA] and trichloro-
ethanol [TCOH]). Pharmacokinetic data were
collected from four male Japanese students
who were exposed to 100 ppm ofTCE for 4
hr. Fernandez et al. (2) published a 5-compart-
ment human model based on controlled
human exposures to TCE vapors for 8 hr rang-
ing from 54 to 160 ppm. TCE in exhaled
breath and the cumulative amount ofTCA
and TCOH excreted in urine were simulated
with this 5-compartment model. Since the
publication of these two human pharmaco-
kinetic models for TCE, several animal and
human pharmacokinetic models for TCE and
its metabolites have been published.
Qualitatively, animals and humans handle
the uptake, distribution, metabolism, and
elimination ofTCE in a similar fashion. This
is a very appealing situation for animal-to-
human extrapolation ofTCE dosimetry based
on validated animal physiologically based
pharmacokinetic (PBPK) models for TCE.
Usually cost and ethical concerns limit the
amount ofpharmacokinetic data that may be
obtained in human volunteers, placing the
burden ofPBPK model development on ani-
mal studies. In addition, animal toxicity
studies are usually employed to assess the
human health hazard potential ofchemicals
such as TCE. Several rodent and human
PBPK models were published for TCE and in
some cases these models were used in cancer
and non-cancer risk predictions. Andersen et
al. (3) collected pharmacokinetic data in rats
and developed a 4-compartment PBPK model
for TCE in rats. Metabolic capacity was esti-
mated in the rats by predicting atmospheric
loss ofTCE in a gas uptake chamber. This was
a landmark physiological model for TCE
because the nonlinear kinetic behavior ofTCE
was quantitatively described with Michaelis-
Menten metabolic parameters. This provided
the ability for a PBPK model to predict TCE
blood and tissue time courses over a wide
range ofexposure concentrations or doses, cor-
responding to flow- and capacity-limited
metabolism ofTCE. Dallas et al. (4) incor-
porated the metabolic parameter estimates
published byAndersen et al. (3) in a 4-com-
partment PBPK rat model. Detailed kinetic
time-course studies ofexhaled breath and
blood were conducted with rats. Bogen (5)
was interested in using a PBPK model for
TCE to predict human health risks associated
with environmental exposure to TCE. He per-
formed a kinetic analysis with TCE using sim-
plified steady-state equations to predict human
health risks for cancer based on the amount of
TCE metabolized. At this time, the U.S.
Environmental Protection Agency (U.S. EPA)
released a risk assessment for TCE that relied
on the estimated amounts ofTCE metabolized
in animal and human studies (6). Koizumi
(7) also predicted human health risks at steady
state using a4-compartment PBPK model and
simulated the amount ofTCE metabolized in
rats and humans. Koizumi collected a limited
amount ofkinetic data for consumption of
TCEdissolved inwater.
More elaborate rodent PBPK models for
TCE were developed to include TCA, a
major metabolite ofTCE. Understanding the
dosimetry ofTCA was thought important
because ofemerging animal toxicity findings
with TCA stemming from identification of
TCA as a byproduct ofwater chlorination.
Fisher et al. (8,9) collected pharmacokinetic
data and developed PBPKpregnancy and lac-
tation models to assess placental and lacta-
tional transfer of TCE and TCA in rats
administered TCE in drinking water, by gav-
age, and as vapors (inhalation). A 7-compart-
ment pregnancy PBPK model was developed
to describe TCE in maternal blood and near-
term fetal blood (8). A linked 3-compart-
ment submodel was used to describe TCA in
maternal and near-term fetal plasma. Transfer
of TCE from the maternal side of the
placenta to the fetus was described with fetal
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blood flow to the placenta. TCA transfer
from the placenta to the fetus was described
as a diffusion-limited process. Both TCE and
TCA concentrations in near-term fetal blood
and plasma, respectively, were somewhat
lower than circulating maternal blood and
plasma concentrations ofTCE and TCA for
oral gavage, inhalation, and drinking water
routes ofexposure to TCE. Fisher et al. (9)
then developed a 5-compartment PBPK
model to describeTCE in maternal blood and
milk, which was linkedwith a4-compartment
model to describe deposition ofTCE in a
nursing pup. TCA in maternal plasma and
milk was described with a 3-compartment
submodel and TCA in pup plasma was
described with a linked 1-compartment sub-
model. Transfer ofTCE into the milk com-
partment was described with a venous
equilibration equation and transfer ofTCA
from the mammary tissue into milk was
described as a diffusion-limited process. TCE
concentrations in milkwerehigher than corre-
sponding maternal blood concentrations and
TCA concentrations in milk were lower than
corresponding maternal plasma TCA concen-
trations. These PBPK models demonstrated
the ability ofexperimentally validated PBPK
models to simulate maternally mediated fetal
(placental transfer) and neonatal (lactational
transfer) dosimetry ofTCE and TCA for dif-
ferent routes ofmaternal exposure to TCE.
In subsequent PBPK modeling efforts,
referred to as first-generation models, with
mice, rats, and humans, Fisher and colleagues
focused on the development andvalidation of
PBPK models for TCE and TCA, with the
majority of the research effort focused on
B6C3F, mice. TCE-induced liver cancer in
the B6C3F, mouse was a critical end point
for the existing 1985 U.S. EPA risk assess-
ment for TCE (6) and was thought to be
important in future risk assessment activities
by the U.S. EPA. Researchers in the late
1980s demonstrated that TCA and
dichloroacetic acid (DCA) administered in
drinking water caused liver tumors in
B6C3F, mice (10). TCA is a major metabo-
lite ofTCE and was thought by Fisher and
colleagues to be the primary carcinogen
responsible for TCE-induced liver tumors in
mice, while DCA was a thought to be a very
minor metabolite. First-generation PBPK
models were developed for TCE and TCA in
male and female mice (11,12) and male and
female rats (11) exposed to TCE vapors or
dosed by gavage with TCE. Allen and Fisher
(13) published a human PBPK model for
TCE and TCA using previously published
pharmacokinetic studies in humans with
TCE and its metabolites. These models
described TCE in blood of mice, rats, and
humans; TCE in exhaled breath ofhumans;
and TCA in plasma of mice, rats, and
humans. These first-generation mice and
human PBPK models forTCE andTCAwill
be discussed in detail.
The most recent advancements in PBPK
modeling of TCE and its metabolites
occurred in mice and humans (14-16). In
the mouse, pharmacokinetic studies were
undertaken in the laboratory to support
development and validation ofsecond-gener-
ation PBPK models for P450-mediated
metabolism ofTCE to chloral hydrate (CH),
DCA, TCA, TCOH, and trichloroethanol
glucuronide (TCOH-b) (14,15). A human
PBPK model was developed using new phar-
macokinetic data collected from eight females
and nine males that were exposed to TCE
vapors (50 or 100 ppm) for 4 hr in a chamber
(16). Blood, urine, and limited exhaled
breath samples were collected to support con-
struction ofthis PBPK model forTCE, TCA,
and TCOH (16). These second-generation
PBPKmodels will be discussed in detail.
Many ofthe toxic and carcinogenic prop-
erties ofTCE result from metabolism ofTCE
(6). A key determinant in elucidating
dose-response relationships for TCE is quan-
tifying the pharmacokinetics of the major
metabolites ofTCE. The use ofPBPK mod-
els in risk assessment is appealing because
these models can be used to estimate target-
organ dose of metabolites in experimental
animals and humans. Five risk assessments
have been recently published for TCE using
PBPKmodels forTCE and its P450-mediated
metabolites and glutathione conjugate. Fisher
and Allen (12) calculated human health risks
for liver cancer using previously published
mice and human PBPK models. Cronin et al.
(17) conducted a Monte Carlo simulation of
the PBPK risk assessment models reported by
Fisher andAllen (12). Clewell et al. (18) pub-
lished the results ofa PBPK risk analysis for
lung and liver cancers based on P450-
mediated metabolites and kidney cancer
based on conjugation of TCE with glu-
tathione. No details of their PBPK model
structure were provided for the glutathione
metabolic pathway. Bogen and Gold (19)
calculated cancer risks for TCE using PBPK
models of Fisher and Allen (12) and Allen
and Fisher (13). Simon (20) constructed a
4-compartment stochastic PBPK model for
TCE with 1-compartment submodels for
TCOH and TCA to predicted blood concen-
trations of TCOH and TCE that would
cause drowsiness in humans.
The objective ofthis paper is to review
and compare recent mice and human PBPK
models for TCE and its major P450-
mediated metabolites. Two human PBPK
models for TCE and its metabolites, Allen
and Fisher (13) and Fisher et al. (16), were
selected for review. Mouse PBPK models
selected for review were those by Fisher et al.
(11), Fisher andAllen (12), Abbas and Fisher
(14), and Greenberget al. (15).
PBPK Model Structures
forTCE and Its P450-
Mediated Metabolites
in the B6C3F1 Mouse
The first generation PBPK models for TCE
in the male and female B6C3F, mouse
(11,12) were 4-compartment models, similar
to styrene, reported by Ramsey and Andersen
(21). The four compartments included fat,
liver, and slowly perfused (muscle) and richly
perfused tissue groups (Figure 1). TCE is
extensively metabolized in the liver by
P4502E1, yielding two major metabolites,
TCA and TCOH. A simple, classical 1-com-
partment model was used to describe the
kinetics ofone metabolite, TCA. A propor-
tionality constant (PO) was used to describe
the stoichiometric yield ofTCA based on the
simulated amount ofTCE that was metabo-
lized (Figure 1). The differential equations
used to describe the compartments are found
in Fisher et al. (11) and Fisher and Allen
(12).
The second-generation PBPK models for
TCE in male B6C3F, mice (14-16) were
6-compartment models consisting of fat,
liver, kidney, lung, and slowlyperfused (mus-
cle) and richly perfused tissue groups (Figure
2A). In addition to the metabolite TCA,
other P450-mediated metabolites (CH,
DCA, TCOH, and TCOH-b) were included
Inhalation
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Figure 1. Schenatic of first-generation PBPK model for
TCE and its oxidative metabolite in mice (11,12) and
humans (13). TCE is inhaled or ingested in drinking
water and for mice administered by oral bolus gavage.
TCE distributes into the body compartments and is either
metabolized in the liverto TCA orexhaled in breath.
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Figure 2. (A) Schematic of second-generation PBPK
model for TCE in mice (14,15) and humans (16). TCE is
inhaled and for mice it is administered by oral bolus gav-
age. (B) Schematic of second-generation PBPK subcom-
partment model structure for metabolites of TCE,
including CH, TCA, DCA, free TCOH (TCOH), and bound
TCOH (TCOH-b) in mice and TCA and TCOH in humans. (C)
Schematic of second-generation PBPK model subcompart-
ment linkages for metabolic pathway of TCE in mice. (D)
Schematic of second-generation PBPK model subcompart-
ment linkages for metabolic pathway ofTCE in humans.
in the second-generation PBPK models. Each
metabolite was described bya 4-compartment
PBPKsubmodel (Figure 2B), which included
the lung, liver, kidney, and the body. The
liver was included in the submodel structure
because ofits role in metabolism and as a tar-
get organ for tumor formation in B6C3F1
mice after chronic oral administration of
TCE (6). The lung was included in the sub-
model structure because the lung is a target
organ for tumor formation in B6C3F1 mice
after chronic exposure to TCE vapors (22).
The kidney's role in the submodel structure
was urinary excretion of metabolites and
assessing metabolite dosimetry. The differen-
tial equations used to describe the submodel
compartments are found in Abbas and Fisher
(14) and Greenberg et al. (15).
The linkage ofthe metabolite submodels
(Figure 2C) was based on a proposed pathway
for metabolism ofTCE taken from Davidson
and Beliles (23). The first metabolic step is
oxidation ofTCE and is the rate-limiting step
in the metabolism of TCE. Subsequent
rearrangement ofTCE after insertion ofthe
oxygen yields a reactive intermediate,
trichloroacetaldehyde, which is then hydro-
lyzed to form CH. CH is either reduced by
alcohol dehydrogenase and aldehyde reductase
in the liver to TCOH or oxidized by aldehyde
dehydrogenase in the liver to TCA. In the
male B6C3F1 mouse, a small fraction of
TCOH is converted to CH, presumably by
alcohol dehydrogenase, and apparently a small
fraction ofTCA is dechlorinated in the liver to
yield DCA. In male B6C3F1 mice, DCA is
rapidly metabolized in the liver to nonchlori-
nated acids (oxalate, glyoxalate, and glycolate)
and monochloroacetic acid (24). The majority
offree TCOH is conjugated with TCOH-b,
which is excreted in urine and feces. The dif-
ferential equations used to describe the com-
partments are found in Abbas and Fisher (14)
and Greenberget al. (15).
A key difference between the first- and
second-generation PBPK mice models for
TCE and its oxidative metabolites was that
PO values were not used to describe the yield
of metabolites in the second-generation
PBPK models. In the second-generation
mouse model, all of the metabolized TCE
was converted to CH at a rate equal to the
rate of oxidation ofTCE. First-order rate
constants were then used to describe the
metabolic conversion of CH->TCA,
TCA-*DCA, TCOH--CH, and a saturable
nonlinear term was used to describe
TCOHR-TCOH-b. First-order terms were
used to describe urinary excretion of CH,
TCA, TCOH, and TCOH-b and fecal
elimination ofTCOH-b.
Derivation of PBPK Model
Parametersfor Mice
Physiological values (e.g., blood flows and tis-
sue and organ volumes) for the first- and sec-
ond-generation PBPK model compartments
were taken from the literature or calculated
when organs or tissues were grouped as one
compartment (Table 1). Chemical-specific
model parameters, such as partition co-
efficients (Table 2), metabolic rate constants,
and urinary excretion rate constants (Table 3)
were determined experimentally in separate
studies or by using pharmacokinetic time-
course data from experiments that were used
to construct and validate the PBPK models.
Fitted rate constant values were determined by
Table 1. Compartment volumes, blood flows, cardiac output, alveolarventilation, and body weightvalues used in the
first- and second-generation PBPK mice models forTCE.
Physiological parameter
Compartment volumes (% bw)
Liver
Lung
Kidney
Slowly perfused
Richly perfused
Fat
Body(formetabolites)
Blood flow (% CO)
First-generation mouse model Second-generation mouse model
Female Male Male
4.0
-a
-a
72.0
5.0
10
-a
Liver 24.0
Lung _a
Kidney -a
Slowly perfused 19.0
Richly perfused 52.0
Fat 5.0
Body (for metabolites) -a
Alveolarventilation (L/hr/kg) 30.0
Cardiac output(L/hr/kg) 30.0
Bodyweight(kg) 0.023-0.030
'Compartment was not included in thefirst-generation PBPK model for mice.
4.0
-a
-a
78.0
5.0
4.0
-a
4.0
0.66
1.8
72.0
3.0
10.0
82.0
24.0
-a
-a
19.0
52.0
5.0
3a
30.0
30.0
0.029-0.033
24.0
100.0
9.0
19.0
43.0
5.0
24.0
28.0
11.6
0.025-0.031
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models.
First-generation mouse model Second-generation mouse model
Female Male Male
Partition coefficient TCE TCE TCE CH TCOH TCOH-b TCA DCA
Blood/air 14.3 13.4 15.9 - - - - -
liver/blood 1.6 2.0 1.7 1.4 1.3 0.6 1.2 1.1
Fat/blood 31.4 41.3 36.4 - - - - -
Richly perfused/blood 1.6 2.0 1.7 - - - -
Kidney/blood -a -a 2.1 1.0 1.0 1.4 0.7 0.7
Slowly perfused/blood 0.5 1.0 2.4 1.4 1.1 1.1 0.9 0.4
Lung/blood -a -a 2.61 1.7 0.8 1.1 0.5 1.2
*Compartment was not included infirst-generation mouse model forTCE.
Table3. Chemical-specific model parameters in miceforfirst- and second-generation PBPK models.
Second-generation
First-generation mouse model mouse model (male)
Model parameters Female Male Oral Inhalation
Oral uptake rate constantforTCE(/hr) 0.9 1.1 3.9a
2.18
0.44
TCA(1 compartment)
Oral
Volume ofdistribution forTCA(L/kg) 0.176 0.238
Plasma elimination rate constant (/hr) 0.062 0.028
PO(fractional yield ofTCA, unitless) 0.09 0.06
Inhalation
Volume ofdistribution (l) 0.176 0.236
Plasma elimination rate constant(/hr) 0.104 0.043
PO (fractional yield ofTCA, unitless) 0.07A0.18 0.07-0.13
TCE
Maximum rate ofTCE-OCH (mg/hr-kg) 23.2 32.7 32.7 32.7
Michaelis-Menten constant(mg/L) 0.25 0.25 4.61 0.25
Fractional uptake of inhaled TCEvapor - - - 0.53
CH
First-order rate, CH-TCOH (/hr/kg) 309 412.39
First-order rate,CH-*TCA(/hr/kg) 115 187.75
First-order urinary excretion of CH(/hr/kg) .06 0.06
TCOH
Maximum rate ofTCOH glucuronidation (mg/hr-kg) 16.5 33.16
Michaelis-Menten constant(mg/L) 15.7 9.47
First-order rate,TCOH-+CH (/hr/kg) 1.32 1.54
First-order urinary excretion ofTCOH (/hr/kg) 1.14 1.14
TCOH-b
First-order urinary excretion ofTCOG (/hr/kg) 32.8 32.8
First-order excretion ofTCOG infeces (/hr/kg) 4.61 4.61
TCA
First-orderTCA--DCA(/hr/kg) 0.35 0.0036
First-order urinaryexcretion ofTCA(/hr/kg) 1.55 2.50
DCA
First-orderDCA-*other metabolites(/hr/kg) 20.5 1.05
'Two first-order rate constants (3.9 and 0.44/hrl described the uptake ofTCE into the liver and a first-order rate (2.18/hr) described the
transferofTCEfrom thefirstto second compartment.
optimization or manually adjusting model rate
constant values until agreement was reached
between predicted and observed pharmacoki-
netic data using Simusolv (Dow Chemical
Company, Midland, MI) or ACSL (MGA,
Inc., Boston, MA).
The vial-equilibrium method (25) was
used to determine in vitro tissue/air and
blood/air partition coefficient (PC) values for
TCE (Table 2). For the first-generation
PBPK model for male and female B6C3F1
mice, F344 rat tissue/air PC values and male
and female mice blood/air PC values were
measured and used as estimates of tissue/
blood PC values for male and female B6C3F1
mice. Mice tissues and blood were used to
determine TCE tissue/air and blood/air PC
values for the second-generation PBPK mod-
els with the exception of using a rat liver/air
PCvalue.
A nonvolatile method (26) was used to
determine in vitro tissue/blood partition co-
efficients for TCE metabolites (Table 2) for
use in the second-generation PBPK model.
Estimates ofTCOH-b tissue/blood PC values
for liver, kidney, lung, and muscle (Table 2)
were determined in vivo from terminal blood
and tissue concentration time-course data for
TCOH-b after oral administration of 1,200
mg/kg ofTCE.
Gas-uptake methodology was employed to
estimate the in vivo metabolic capacity for oxi-
dation ofTCE in B6C3F, mice (Table 3). A
series of atmospheric loss curves were gener-
ated for male and female B6C3F, mice, rang-
ing from 300 to 10,000 ppm initial
concentrations, and analyzed using the first
PBPK model for TCE to estimate the
Michaelis-Menten constants, Vm,,, and Km.
The Vm,, values for male and female mice
were 32.7 and 23.2 mg/kg/hr, respectively,
scaled to bw07. The Kmvalue was estimated to
be 0.25 mg/L for both male and female mice.
The Vmaxc value obtained in the first-
generation model for male mice was used in
the second-generation models. However,
Abbas and Fisher (14) adjusted the value of
Km to a value of4.6 mg/L to provide an ade-
quate fit of the blood-time-course data for
TCE. The adjustment of the Km value for
TCE is disconcerting, since the only other
reported value for Km is 0.25 mg/L (Table 3).
This adjustment in Km value reflects the diffi-
culty in describing TCE blood-time-course
data for mice dosed by oral intubation with
TCE dissolved in corn oil. There is no reason
to suspect that corn oil alters the Km value for
oxidation ofTCE; rather this adjustment in
Km reflects an oversimplification ofthe model
structure for describing oral uptake ofTCE
dissolved in corn oil. In the first-generation
PBPK model, TCE blood-time-course data
for mice dosed with TCE dissolved in corn oil
could not be described with a single oral
uptake rate constant. In the second-generation
PBPK model, TCE blood-time-course data
were adequately described using two oral
uptake rate constants representing both rapid
and slow oral uptake phases (Table 3) and
increasing the Kmvalue from 0.25 to 4.6 mg/L.
Intravenous (i.v.) dosing studies (100
mg/kg) with CH, TCOH, TCA, or DCA
were initially conducted to estimate apparent
metabolic rate constant values for each
metabolite (27). Metabolic rate constant val-
ues for each administered metabolite were esti-
mated by visual fitting ofblood-time-course
data for the administered chemical and its
metabolic products using the submodel struc-
ture (Figure 2B) and metabolic pathway link-
age (Figure 2C). DCA, TCOH, TCOH-b,
and TCA were measured in mice dosed with
CH (28), but in later experiments DCA was
not measured as a metabolite ofCH, TCA,
orTCOH in maleB6C3F, mice (29).
A large number of male B6C3F, mice
were given bolus doses ofTCE dissolved in
corn oil to construct and validate the oral
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dosing second-generation PBPK model
(14). Blood, tissues, and urine were col-
lected for analysis ofTCE and metabolites
in four dose groups (2,000, 1,200, 600, and
300 mg/kg). The 1,200-mg/kg dose group
was used to develop the PBPK model for
TCE and its P450-mediated metabolites.
The following rate constants were obtained
by adjusting rate constant values until an
adequate visual fit of the time-course data
could be obtained: urinary rate constant val-
ues for CH, TCOH, TCOH-b, and TCA,
2-compartment oral uptake rate constant
values for TCE, first-order fecal elimination
ofTCOH-b, and a first-order metabolic rate
constant value for metabolism of DCA.
Other metabolic rate constant values in the
PBPK model were visually fitted rate con-
stant values taken from i.v. dosing studies
(27). Abbas and Fisher (14) showed mea-
sured and model-simulated pharmacokinetic
profiles for TCE in blood and fat, TCOH
and CH in blood and lung, TCA and DCA
in blood and liver, and TCA in urine and
TCOH-b in blood and urine. Low concen-
trations of DCA were measured in mice
administered TCE by gavage, and its forma-
tion was kinetically described as reductive
dechlorination ofTCA.
Greenberg et al. (15) exposed mice for
4 hr to TCE vapor concentrations of 100
and 600 ppm. Measured and model-
predicted time-course concentrations are pre-
sented for TCE in blood, TCA in liver and
blood, TCOH in blood and lung and
TCOH-b in blood, and DCA in blood and
liver. Model parameter values were taken
from Abbas and Fisher (14) or in some cases
adjusted to obtain better visual agreement
between model simulation and observation
(Table 3). In this PBPK model, fractional
uptake ofTCE (53%) was used to describe
inhalation ofTCE vapors in mice. Exhaled
breath studies were conducted after inhala-
tion ofTCE vapors to provide supporting
evidence for fractional uptake ofTCE in the
lung. Model simulations suggested that only
about 50% of the inhaled TCE vapor was
taken into systemic circulation in the lung in
theB6C3F, mouse.
Table 3 provides a comparison of the
second-generation PBPK model parameters
for inhalation ofTCE vapors (15) and oral
ingestion ofTCE dissolved in corn oil (14).
The rate constant values for several parame-
ters differ between the two routes ofadminis-
tration. In the inhalation model the rate
constant values for formation ofTCA and
TCOH and for glucuronidation ofTCOH
to TCOH-b are greater than in the oral dos-
ing model. In addition, rate-constant values
associated with formation and metabolism of
DCA are less in the inhalation model
compared to the oral dosing model. Because
ofthe dynamic nature ofa bolus gavage dose
and the complexity of oral absorption of
TCE dissolved in corn oil, the 4-hr inhala-
tion study provides a more suitable data set
for estimating the kinetic rate constant val-
ues. Further simulation work is needed to
merge the model parameters into a single set
ofparameters. Data from the gavage dosing
study should be simulated with the model
parameters for inhalation ofTCE to resolve
differences between model parameter esti-
mates for each route of exposure and to
delineate the influence ofthe corn oil vehicle
on estimating model parameter estimates.
Resolution of route-to-route differences in
rate constant values that describe formation
and metabolism ofDCA remains unclear at
this point because ofanalytical uncertainty in
measuring trace quantities ofmetabolically
formed DCA in the presence of relatively
high concentrations ofTCA.
Ability ofthe PBPK Models
to Predict Pharmacokinetics
ofTCE and Its Metabolites
in Mice
The first-generation mice PBPK models for
TCE in blood and TCA in plasma were
developed forgavage dosingofTCEdissolved
in corn oil (12) and for inhalation ofTCE
vapors (11). Male and female mice were gav-
age dosed with either 487, 973, or 1,947
mg/kg. In other experiments female mice
were exposed for 4 hr to TCE vapor concen-
trations ofeither 42, 236, 368, or 889 ppm
and male mice to TCE vapor concentrations
ofeither 110, 297, 368, or 747 ppm. The
blood concentrations ofTCE were not ade-
quatelysimulated by the PBPK models in the
gavage-dosed or vapor-exposed male and
female mice. The inability of the PBPK
model forTCE to predict oral uptake kinetics
by a simple first-order process was attributed
to a vehicle effect (corn oil). In general the
PBPK model overpredicted the blood levels
ofTCE for inhalation. The reason for the
observation was unknown.
TCA model simulations were not predic-
tions per se but fitted simulations for gavage
dosing andinhalation routes ofexposure. With
a 1-compartment model, fitted simulations of
the production and systemic dearance ofTCA
were in good agreement with observed TCA
plasma concentrations for both genders of
gavage-dosed mice. For the TCE vapor-
exposed maleand female mice, thefitted simu-
lations ofTCA plasma concentrations were in
agreement with experimental findings.
Systemic clearance ofTCA was measured for
20 hr postexposure for thevapor-exposed mice
and for44-70 hrforthegavage-dosed mice.
The second-generation male mice models
were more challenging because several more
metabolites were included in the model
structure. For the gavage-dosed mice (14),
model predictions were compared to obser-
vations for TCE corn oil gavage doses of
300, 600, 1,200, and 2,000 mg/kg. Model
predictions for TCE and its metabolites in
blood, tissues, and urine were in general
agreement with observations in most simula-
tions, but in a few cases, prediction and
observation were not in close agreement.
Discrepancies between model predictions
and observations are expected, since the phi-
losophy is to develop a PBPK model that is
robust and can describe a wide range ofdata
sets with a single set ofmodel parameters.
Modest model discrepancies compared to
measured values were reported for clearance
ofTCOH from lung in the two lowest dose
groups, TCA concentration in blood ofthe
300-mg/kg dose group, and the cumulative
amount ofTCA excreted in urine from the
2,000-mg/kg dose group.
Abbas and Fisher (14) used asingle meta-
bolic rate constant (calculated from the
1,200-mg/kg dose group) to describe forma-
tion ofDCAvia dechlorination ofTCA in all
gavage dose groups. This resulted in the slight
overprediction of DCA concentrations in
blood and liver in the 600- and 300-mg/kg
dose groups. The authors suggested that this
discrepancy between model simulation and
observation might be related to the influence
ofthe vehicle (corn oil) on the dose rate of
deliveryofTCE to the liver.
Greenberg et al. (15) exposed mice to
100 and 600 ppm ofTCE vapors for 4 hr.
The PBPK model was generally successful
with a few exceptions in predicting the
kinetic profile for TCE and its oxidative
metabolites after inhalation ofTCE vapors.
Peak TCOH concentrations in lung tissue
were underpredicted by a factor of2 for the
100-ppm exposure group and TCOH-b sys-
temic clearance from blood was slightly
greater than predicted by the model for both
exposure groups. To avoid gross overpredic-
tions in TCE blood concentrations, frac-
tional uptake ofinhaled TCE was employed
(53%). Supporting experimental evidence for
fractional uptake ofTCE into lung blood
was obtained by conducting exhaled breath
experiments. This modeling approach has
been used previously for polar organic chem-
icals (30). To validate the hypothesis offrac-
tional uptake of TCE in mice, further
experiments are required in which exhaled
breath is measured during inhalation ofTCE
in mice.
PBPK Model Structures for
TCE and Its P450-Mediated
Metabolites in Humans
The first-generation PBPK model for TCE
in humans (13) was a 4-compartment
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model with the same model structure as the
first-generation PBPK model for mice
(Figure 1). TCA was described with a classi-
cal 1-compartment model similar to the
mice. In the human, the yield ofTCA was
accounted for by conversion ofTCOH to
TCA and by conversion ofTCE (via CH) to
TCA, which was not explicitly determined
in the first-generation mouse model. The
human PBPK model for TCE and its oxida-
tive metabolite, TCA, was developed using
published human pharmacokinetic data
taken from controlled TCE vapor exposures
and studies in which sodium trichloroacetate
was administered by i.v. drip and CH and
TCOH by oral administration.
In the second-generation human model
(16), six compartments (liver, lung, kidney,
and richly perfused and slowly perfused tis-
sues) were used to describe the pharmaco-
kinetics of TCE (Figure 2A). Only two
metabolites ofTCE, TCA and TCOH, were
incorporated as submodels (Figure 2D)
because TCA and TCOH were the only
measured metabolites in blood except for
intermittent trace amounts of DCA in
plasma. Four compartments (body, liver,
kidney, and lung) were used to describe these
metabolites (Figure 2B). The TCE human
model was linked to the submodels, as
shown in Figure 2D. POs were used to
describe the yield ofTCA and TCOH, simi-
lar to the first-generation human PBPK
model forTCA (Figure 1).
Derivation of PBPK Model
Parametersfor Humans
The first-generation model (13) was devel-
oped using pharmacokinetic data reported in
the literature for humans. Simulations were
conducted using SCoP software (National
Biomedical Simulation Resource, Duke
University, Durham, NC). The human V,
value (14.9 mg/kg/hr) was an optimizedvalue
based on exhaled breath (TCE), TCE
blood-time-course data, and TCA concentra-
tions in plasma and urine.
The amount ofTCOH produced from
TCA was estimated by pharmacokinetic
analysis using TCA plasma-time-course data
from two volunteers given repeated oral
administration ofTCOH (31). The volume
of distribution ofTCA was estimated by
pharmacokinetic analysis ofTCA plasma
concentrations in three humans dosed with
sodium TCA by i.v. drip (32). Published
controlled TCE vapor exposures in humans
were used to develop and validate the human
PBPK model for TCE using exhaled breath
and blood concentration data.
The second-generation PBPK model for
TCE inhumanswasbased on recent4-hrTCE
inhalation exposures conducted with nine male
and eight female consenting volunteers (16).
Thewhole-bodyexposureswereconducted in a
chamber described by Raymer et al. (33).
Several blood samples were taken from each
individual byvenous catheter during the expo-
sure period andfor 18 hrpostexposure in addi-
tion to urine samples. Alveolar breath samples
were collected from a few ofthe exposed vol-
unteers after the 4-hr exposure using methods
described by Pleil and Lindstrom (34). After
this period the volunteers returned to the
Research Triangle Institute (Research Triangle
Park, NC) once each day for 3 days to deliver
their voided urine and to have blood drawn
byvenipuncture.
The following chemicals were analyzed
for in blood and urine: TCE, CH, TCOH,
TCOH-b, TCA, and DCA using methods
reported by Abbas and Fisher (14) and by
Ketcha et al. (35). TCE, TCOH, and TCA
were found in all blood samples, TCOH-b
and TCA in all urine samples, and TCE in
exhaled breath samples. DCA was found
intermittently above the limit ofdetection
(> 4 pg/L) in the blood ofthree ofnine males
and two ofeight females, ranging from 5 to
12 1ug/L.
Blood/air partition coefficient values for
TCE in the second-generation model were
determined by vial equilibration (25) for sev-
eral ofthe male and female volunteers (Table
4). Human tissue/air PC values forTCEwere
determined for lung, liver, kidney, and fat
using fresh chilled tissues from donors. Other
donors provided liver, kidney, muscle, and
lung tissue to measure TCOH and TCA PC
values in tissues. Tissue/media and blood/
media PC values for TCOH and TCA were
determined via a nonvolatile technique (26).
Fresh blood was obtained from two female
donors to measure the TCOH and TCA
blood/media PC values.
Using the model structure in Figure 2A
and physiological model parameter values
given in Table 5, the optimized values for
Vm.,c, (mg/kg/hr, allometrically scaled, bw075)
and Km (mg/L) were obtained for each gender
by fitting predicted with observed mixed
venous TCE blood concentrations (Table 6).
To obtain adequate model predictions of
TCA and TCOH blood-time-course
kinetics, the optimized Vmaxc values were
increased from 2.30 and 4.74 mg/kg/hr for
males and to 4.0 and 5.0 mg/kg/hr for
Table 4. Partition coefficient values forTCE in first- and
second-generation PBPK human models and for TCOH
and TCA in second-generation PBPK human model.
First-generation Second-generation
Partition human model human model
coefficient Male Female Male
Trichloroethylene
Blood/air 9.20 9.13 11.15
Liver/blood 6.82 5.92 4.85
Kidney/blood -a 1.32 1.08
Lung/blood _a 0.48 0.39
Body(muscle)/blood 2.35 1.68 1.38
Fat/blood 73.3 63.88 52.34
Trichloroethanol (free)
Liver/blood 0.59 0.59
Kidney/blood 2.15 2.15
Lung/blood 0.66 0.66
Body(muscle)/blood 0.91 0.91
Trichloroacetic acid
Liver/blood 0.66 0.66
Kidney/blood 0.66 0.66
Lung/blood 0.47 0.47
Body(muscle)/blood 0.52 0.52
&Compartment was not included in the first-generation PBPK
human model.
Table 5. Compartmentvolumes, blood flows, cardiac output, alveolarventilation, and bodyweight values used in the
first- and second-generation PBPK human models forTCE.
First-generation human model Second-generation human model
Physiological parameter Male Female Male
Compartment volumes (% bw)
Liver 2.6 2.4 2.6
Lung -a 1.4 1.4
Kidney -a 0.47 0.4
Slowly perfused 62 47.0-61.0 55.0-72.0
Richly perfused 5 4.7 4.6
Fat 19 21.0-35.0 10.0-27.0
Body(formetabolites) -a 92.0 92.0
Blood flow (% CO)
Liver 26 18.7 24.0
Lung -a 100.0 100.0
Kidney -a 17.5 19.7
Slowly perfused 25 17.3 19.2
Richly perfused 44 39.8 32.3
Fat 5 6.7 4.8
Body(formetabolites) -a 68.3 56.3
Alveolarventilation (L/hr/kg) 12.9 18.1 18.6
Cardiac output(l/hr/kg) 15.0 17.7 15.9
Bodyweight(kg) 70 48.6-67.3 52.3-82.7
aCompartment was not included in thefirst-generation PBPK model for human.
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females, respectively; Km values were set to
the optimized of 1.80 and 1.66, respectively.
The PO constant values for TCOH and
TCA were set to 0.9 and 0.1 in males and
females. That is, 90% of the oxidized TCE
was converted to TCOH and 10 % to TCA.
A large fraction ofthe TCOH is converted to
TCA in humans (31), presumably via back
conversion ofTCOH to CH. This back con-
version ofTCOH to TCA was described as a
first-order process (Table 6).
Urinary excretion ofTCA and TCOH-b
was variable between volunteers. This suggests
that individual variability may exist in the ini-
tial metabolic step for TCE (P450 CYP2E1-
mediated oxidation) or in the metabolic steps
required for the formation and metabolism of
its major metabolites. In addition, urinary
excretion rates of the metabolites may vary
between individuals. The pharmacokinetic
determinants responsible for the observed
variability in urinary excretion ofmetabolites
are unknown at this time. Therefore, for the
sake ofsimplicity, individual variability was
characterized by adjusting only urinary excre-
tion model parameters for TCOH and TCA.
For each individual a fitted first-order urinary
excretion rate constant was used to describe
urinary excretion ofTCA (Table 6). A com-
posite, nonlinear, Michaelis-Menten velocity
term was used to collectively describe glu-
curonidation ofTCOH and urinary excretion
ofTCOH-b (Table 6).
Ability ofthe PBPK Models
to Predict Pharmacokinetics
ofTCE and Its Metabolites
in Humans
The ability of the human model to simulate
the pharmacokinetics ofTCE and its meta-
bolites is briefly discussed. Exhaled breath
concentrations ofTCE were not adequately
predicted by either the first- or second-
generation human PBPK models. Exhaled
breath concentrations dropped more rapidly
than were predicted immediately after cessa-
tion ofvapor exposure to TCE. In the first-
generation model for the adult male, Allen
and Fisher (13) obtained good agreement
between model-predicted (or -fitted) and
mean observed TCE concentrations in blood
and TCA concentrations in plasma and the
mean cumulative amount ofTCA excreted
in urine for volunteers exposed to TCE
vapors. In the second-generation PBPK
model for male and female adults (16), phar-
macokinetic profiles for TCE and its
metabolites were available for each individ-
ual. Gender-specific and individual-specific
model predictions (or fits) ofTCE, TCOH,
and TCA in blood were in general agreement
with observed data for individuals exposed to
100 ppm TCE. TCE blood concentrations
were underpredicted by a factor of 2 for
individuals exposed to 50 ppm TCE.
Comparison of First- and
Second-Generation PBPK
Models in Mice and Humans:
Dosimetry ofTCA
Because of the importance ofTCA as a pro-
posed ultimate carcinogen for TCE-induced
liver tumors in mice, a comparison of the
TCA dosimetry and model sensitivity is pre-
sented for model-predicted TCA plasma and
whole-blood levels. TCA was measured in
plasma for the first-generation models and in
whole blood for the second-generation PBPK
models. The reason for the disparity between
first- and second-generation mice and human
model-predicted TCA concentrations in
plasma and blood, respectively, is that TCA
plasma and whole-blood measurements can
differ by at least 2-fold because of uptake of
TCA into red blood cells (32).
The first- and second-generation PBPK
models for male adults and male mice were
compared by presenting simulation results for
TCA in plasma and whole blood for a 4-hr
100-ppm vapor exposure to TCE. The
Table 6. Chemical-specific model parameters in humans for first-generation PBPK model (TCE and TCA) and for
second-generation PBPK model (TCE, TCA, TCOH).
First-generation human model Second-generation human model
Model parameter for human Male Female Male
TCE
Vmaxc(mg/hr-kg) 14.9 5.0 4.0
K,(mg/L) 1.5 1.66 1.80
TCA
Volume of distribution (L) 0.34-0.0034 x bw
Fractional yield (unitless)a 0.33 0.1 0.1
Urinary excretion rate constant (/hr)a 0.028 0.6-3.0 0.13-2.0
TCOH
Fractional yield (unitless) 0.9 0.9
TCOH-ITCA(/hr) 10.0 10.0
Urinary excretion rate constant
(mg/hr-kg) forTCOH-b 0.4-2.2 0.35-4.0
'Fractional yield and urinary excretion rate constants forthe first- and second-generation PBPK models are not comparable because of
model structure differences.
human male model simulated eight individual
males (16). Daily area-under-the-concentration
curve (AUC) values for TCA in plasma or
blood in humans were calculated from a
10-day simulation period. In addition, the
first- and second-generation PBPK models
for gavage dosing ofTCE were compared by
simulating TCA in plasma and whole blood
for a 400-mg/kgTCE single dose.
In humans the predicted peakconcentration
ofTCA in plasma (first-generation model) was
greater than the predicted peak TCA concen-
tration in blood (second-generation model)
(Figure 3). The TCA plasmaAUC value using
the first-generation PKPK model was 367
mg/L/day and for the second-generation
model, the blood TCA-AUC values (n = 8)
ranged from 74 to 343 mg/L/day with a mean
plasmavalueof222 mg/L/day (Table 7).
With this TCE exposure scenario, the
most sensitive first-generation human model
parameter for predicting AUC for TCA in
plasma was the fractional yield ofTCA from
TCE (0.33, Table 6). A 5% increase in this
value resulted in a 4.2% increase in the TCA
plasma AUC value. When all other model
parameter values were individually increased
by 5%, the percent change in the TCA plasma
AUC was negligible. In the second-generation
human PBPK model the most sensitive model
parameter for predicting AUC for TCA in
blood was the body (muscle)/air partition
coefficient value for TCA (0.52, Table 4). A
5% increase in this value resulted in a 3.6%
decrease in the TCA bloodAUC value. Other
model parameters in the second-generation
PBPK model were not as sensitive for
predictingAUC for TCA in blood.
In maleB6G3F, mice, the first-generation
model-predicted peak TCA plasma con-
centrations were higher than the second-
generation model-predicted TCA blood
30
24-
1st generation model
(plasma)
12- 2nd generation model
O 5s 100 150 200 250
TIME (hours)
Figure 3. Computer simulation of TCA in plasma (first-
generation PBPK model) and whole blood (second-gener-
ation PBPK model) resulting from a simulated 4-hr,
100-ppm constant concentration TCE vapor exposure in
male humans.
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model)curves forTCAafter administration ofTCE to male mice and humans.
First-generation model predicted Second-generation mc
Simulated administration ofTCE AUC forTCA in plasma (mg/L/day) AUC forTCA in blooc
Mice (male)a
Gavage (400 mg/kg) 747.0 489.
Inhalation (100 ppm, 4hr) 428.0 190.
Human (male)b
Inhalation (100 ppm, 4hr) 367.0 222.0 (avera
74-343 (r
'Computer simulations for male mice dosed by bolus gavage with 400 mg/kg TCE or exposed to 100 ppm TCE vapors
10-daycomputer simulation for male humans exposed to 100 ppm TCE for4 hr/day.
concentrations. Figures 4 and 5 depict the
simulated TCA plasma and blood-time-
courses for the first- and second-generation
male inhalation and gavage mice models.
First-generation model-predicted AUC values
for TCA in plasma were also greater than the
second-generation model-predicted AUC
values forTCA in blood (Table 7).
The most sensitive model parameter for
the first-generation gavage model for the male
mouse was the volume ofdistribution for
TCA (0.238 L/kg, Table 3). A 5% increase in
volume ofdistribution resulted in a 4.8%
decrease inAUC value for TCA in plasma. In
the first-generation male mouse inhalation
model, a 5% increase in volume ofdistribu-
tion for TCA (0.236 L/kg, Table 3) resulted
in a 4.9% decrease in the model-predicted
AUC value for TGA in plasma. In addition, a
5% increase in the fractional yield ofTCA
from TCE (PO = 0.07, Table 3) resulted in a
4.9% increase in the AUC value for TCA in
plasma. In the second-generation male mouse
gavage model, blood flows to the liver and
kidney (Table 1) were the most sensitive
model parameters for predicting blood con-
centrations ofTCA. The volume ofthe body
compartment (82% bw, Table 1) and the
body (muscle)/blood PC value for TGA (0.9,
50-
40-
30
Istgeneraton model
1120 I \ ~~~~~(plasma)
20-
|/2ndgeneationmote
(blood)
0 4.8 9.6 14.4 19.2 24.0
TINE (hours)
Figure 4. Computer simulation of TCA in plasma (first-
generation PBPK model) and whole blood (second-gener-
ation PBPK model) resulting from a simulated 4-hr,
100-ppm constant concentration TCE vapor exposure in
male mice.
Table 2) were the most sensiti
parameters for predicting blood (
tion ofTCA in the second-general
inhalation model. A 5% increase
ume ofthe body compartment re
3.5% decrease in the blood conce
TGA, and 5% increase in the body
value for TCA resulted in 3.5%
the blood concentration ofTGA.
Summary
Several important features are pre.
second-generation PBPK models f
rodents and humans. These mode
for additional metabolites in
humans that are toxicologically
Model validation in mice includec
tissues for TCE and its metaboliti
tion to blood or plasma. The first-
models relied only on pla
blood-time-course data. New hu
macokinetic data were collectt
second-generation human moc
pharmacokinetic data sets were ext
relied on improved analytical (
methods. DCA was identified a
metabolite of TCE in some in
Significant variability in metaboli
in blood and urine was found
75-
60-
745 1
lstgenerationmodel
30-
15- | 2ndgeneration
(blood)
0 4.8 9.6 14.4
Time (hours)
Figure 5. Computer simulation of TCA in
generation PBPK model) and whole blood (s
ation PBPK model) resulting from a simulate
bolus gavage dose ofTCE in male mice.
nd-generation individuals exposed to similar concentrations
of TCE. This finding suggests that the
Adel predicted dosimetry ofTCE and its metabolites is more
d(mg/L/day) variable in humans than in experimental
rodents. However, this variability can be
0 quantified and incorporated into human
0 PBPKmodels intended for risk assessment.
The second-generation PBPK models for
ge) n= 8 TCE describe the pharmacokinetics ofTCE
range) and its P450-mediated metabolites using a
for 4 hr/day. bA complex metabolic scheme, which accounts
for species differences. Although significant
progress has been attained in formulating
ive model mathematical models to quantitatively
concentra- describe the uptake and metabolism ofTCE
tion mouse in rodents and humans, further laboratory
in the vol- studies and modeling efforts are warranted.
sulted in a Lack of knowledge about mechanisms of
ntration of action for the observed toxicity caused by
-blood PC TCE in laboratory animals and humans
increase in remains the greatest barrier to direct imple-
mentation of the PBPK models for risk
assessment purposes. PBPK modeling ofthe
glutathione pathway for TCE warrants fur-
sent in the ther attention beyond the efforts presented
For TCE in by Clewell et al. (18) to reduce the uncer-
els account tainty associated with dose-response analysis
mice and of kidney tumors. Time-course kinetic
z relevant. studies are needed for this metabolic path-
A analyzing way. Studies are needed to determine what
zes in addi- physiological or biochemical factors are
-generation responsible for the observed human variabil-
sma and ity in urinary excretion ofTCOH-b and
man phar- TCA (16). DCA has been reported as a
ed for the metabolite in rodents and now humans.
tel. These Analytical difficulties in the analysis ofDCA
tensive and in biological tissues (35) have recently been
chemistry reported as errata to published articles
5S a minor (29,36). Further research is needed to deter-
dividuals. mine the origin of DCA in rodents and
ite profiles humans administered or exposed to TCE.
1 between Recently, Beland et al. (37) reported that
DCA was not produced in mice and rats
administered CH. However, Muralidhara
and Bruckner (38) reported significant
amounts of DCA formation in mice dosed
with TCE. Further research is needed to bet-
ter understand the role ofTCOH and CH in
lung tumor formation of mice exposed to
TCE vapors.
The PBPK models for TCE and its
glutathione and P450 metabolites should be
integrated into a single PBPK model for the
risk assessment ofTCE. Critical features of
each model should be retained and the PBPK
model should be constructed with a priori
assumptions about extrapolation require-
ments. In summary, substantial advances
9;.2 24.0 have occurred over the last 10 years inunder-
standing the dosimetry of TCE and its
plasma (first- metabolites in rodents and humans. These
;econd-gener- advances in PBPK modeling can be used
ad 400-mg/kg today in crafting scientifically sound public
health decisions forTCE.
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